Day: March 6, 2021

Company announcement no. 13-20216 March 2021With reference to section 31 of the Danish Capital Markets Act it is hereby disclosed that North Media A/S has crossed below the 10%-threshold regarding North Media A/S’ possession of treasury shares.North Media A/S’ possession of treasury shares has crossed below the 10%-threshold due to the company’s ongoing sale of treasury shares made in connection with employees exercising the first tranche in the company’s share option programme. As a consequence of the sales of treasury shares, North Media A/S is today in possession of 9.68 % of the voting rights and share capital of the company.For further informationKåre Wigh, Group Executive Officer & CFO, mobile +45 25 65 21 45This document is an unofficial translation of the Danish original. In the event of any inconsistencies, the Danish...

Selskabsmeddelelse nr. 13-20216. marts 2021Med henvisning til § 31 i Kapitalmarkedsloven oplyses det hermed, at North Media A/S er krydset ned under 10%-grænsen i forhold til North Media A/S’ besiddelse af egne aktier.North Media A/S’ beholdning af egne aktier er faldet til under 10% som følge af selskabets løbende salg af egne aktier, der er foretaget i forbindelse med, at medarbejdere har udnyttet første tranche i selskabets aktieoptionsprogram.Som følge af salgene af egne aktier besidder North Media A/S d.d. 9,68 % af stemmerettighederne og aktiekapitalen i selskabet.Yderligere oplysningerOrdførende koncerndirektør & CFO Kåre Wigh, mobil 25 65 21 45

High Lung Levels of Active Triphosphate Predicted with Oral AT-527 for COVID-19 PatientsData Supportive of AT-527 550 mg BID Dosing RegimenBOSTON, March 06, 2021 (GLOBE NEWSWIRE) — Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today presented results from the Phase 1 study of AT-527 in healthy volunteers at the 28th Annual Conference on Retroviruses and Opportunistic Infections (CROI) in a Science Spotlight presentation. AT-527 is an orally administered, direct-acting antiviral developmental agent derived from Atea’s purine nucleotide prodrug platform and is in Phase 2 clinical development for the treatment of COVID-19. AT-527 targets SARS-CoV-2 ribonucleic acid (RNA) polymerase (nsp12), a highly conserved gene which is responsible for both viral RNA replication and transcription....

Steve Muehler, Founder and Senior Managing Member of Private Placement Markets, today announced that its popular “EquityLock Commercial Value Protection Plans” and “EquityLock Residential Value Protection Plans” will be available throughout the United States after being temporarily halted in July of 2020 amid the COVID-19 Pandemic and general global market uncertainty. Steve Muehler stated, “with the job numbers today and the first real glimpse of real data showing a true economic recovery, and with the vaccine penetration not just here in the United States, but around the world, coupled with the fact that the U.S. Housing Market is currently experiencing a severe housing shortage, all these elements along with other data has given us the raw data needed to put the EquityLock Value Protection Plan Programs back onto the market. Obviously...

NEW YORK, March 05, 2021 (GLOBE NEWSWIRE) — Hu Products announced today a nationwide voluntary recall in the United States of a single production lot of the Hu Chocolate Covered Hunks – Sour Goldenberries Product (4 oz. bag) because some packages may contain undeclared almonds that were inadvertently added to the product during manufacturing. People who have an allergy or severe sensitivity to almonds run the risk of serious or life-threatening allergic reaction if they consume these products.This recall is limited solely to the Hu Chocolate Covered Hunks – Sour Goldenberries Product (4 oz. bag), which was sold in retail stores and online in the United States. No other Hu products are affected, and this recall does not affect products in countries other than the United States.     

KELOWNA, British Columbia, March 05, 2021 (GLOBE NEWSWIRE) — Allied Corp. (the “Company” or “Allied”) (OTCQB: ALID) is pleased to announce that it has retained the services of IDR Marketing, Inc. to provide public relations strategies, brand awareness, financial and digital marketing services to the Company.The marketing awareness services provided by IDR will be aimed at maintaining and building the profile of Allied Corp. through traditional press initiatives, advertising directives and social media strategies.“IDR Marketing has a proven track record of creating quality media and content across multiple platforms, married with wide-scale distribution, to get our story out to the science, health and investment communities. We look forward to working with the company to grow our profile in America. We believe it’s time to deliver...

VANCOUVER, British Columbia, March 05, 2021 (GLOBE NEWSWIRE) — Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company is pleased to announce that it has increased and completed its previously announced non-brokered private placement of units (the “Units”), and has issued an aggregate of 11,260,040 Units at the price of CDN $0.25 per Unit, raising gross proceeds of CDN $2,815,010 (the “Offering”).Each Unit is comprised of one Class A common share (a “Share”) and one Share purchase warrant. Each whole warrant will entitle the holder to acquire one additional Share at a price of CDN $0.40 per Share until March 5, 2023 (the “Expiry Date”).At any time after July 5, 2021 and prior to the Expiry Date, the Warrants are subject...